<DOC>
	<DOCNO>NCT01550744</DOCNO>
	<brief_summary>The purpose study assess effect extend maintenance dosing interval beyond 12 week clinical efficacy safety ustekinumab subject moderate-to-severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Ustekinumab Evaluate `` Subject-tailored '' Maintenance Dosing Approach Subjects With Moderate-to-Severe Plaque Psoriasis</brief_title>
	<detailed_description>In study , proportion subject receive study agent recommend dose interval ( 45mg subject less equal 100kg , 90mg subject great 100kg ; every 12 week 2 starter dos Weeks 0 4 ) . The majority subject opportunity receive study agent less frequently randomization period depend subject 's response . The study consist 4-week screening period ; 28-week open-label run-in period ; double-blind treatment period Week 28 Week 104 ; 12 week post-treatment period ; 20-week safety follow-up . Participants randomize double blind period one two study group . Group 1 participant receive injection study medication 12 week dose interval . Group 2 participant undergo placebo withdrawal may receive study agent extend interval great 12 week . During double-blind treatment period , subject Groups 1 2 receive placebo necessary maintain blind .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Key Eligibility Criteria Male female Have diagnosis plaquetype psoriasis least 6 month prior first administration study agent ( subject concurrent psoriatic arthritis may enrol ) . Have plaquetype psoriasis cover least 10 % total BSA screening time first administration study agent . Have PGA score â‰¥ 3 screening time first administration study agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>STELARA</keyword>
	<keyword>Skin disease</keyword>
	<keyword>Monoclonal</keyword>
</DOC>